Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rallybio Corporaton (RLYB)

Rallybio Corporaton (RLYB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,529
  • Shares Outstanding, K 5,290
  • Annual Sales, $ 860 K
  • Annual Income, $ -8,980 K
  • EBIT $ -33 M
  • EBITDA $ -34 M
  • 60-Month Beta -1.13
  • Price/Sales 50.68
  • Price/Cash Flow N/A
  • Price/Book 0.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-1.68
  • Growth Rate Est. (year over year) +59,564.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.90 +13.54%
on 03/30/26
11.49 -21.93%
on 03/03/26
+1.43 (+18.97%)
since 02/27/26
3-Month
3.67 +144.41%
on 02/17/26
11.49 -21.93%
on 03/03/26
+3.47 (+63.07%)
since 12/26/25
52-Week
1.76 +409.43%
on 04/08/25
11.49 -21.93%
on 03/03/26
+3.85 (+75.17%)
since 03/28/25

Most Recent Stories

More News
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RLYB : 8.97 (+11.57%)
VRME : 0.8399 (+8.89%)
AES : 14.09 (+0.50%)
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio Corporation (NasdaqCM:...

RLYB : 8.97 (+11.57%)
Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RLYB : 8.97 (+11.57%)
KW : 10.82 (-1.46%)
AES : 14.09 (+0.50%)
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would...

RLYB : 8.97 (+11.57%)
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed...

RLYB : 8.97 (+11.57%)
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed...

RLYB : 8.97 (+11.57%)
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical...

RLYB : 8.97 (+11.57%)
Rallybio Announces Reverse Stock Split of Common Stock

Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and...

RLYB : 8.97 (+11.57%)
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash...

RLYB : 8.97 (+11.57%)
Rallybio (RLYB) Receives a Hold from Evercore ISI

In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Hold rating on Rallybio, with a price target of $1.00. The company’s shares closed yesterday at $0.56.Elevate Your Investing...

RLYB : 8.97 (+11.57%)

Business Summary

Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.

See More

Key Turning Points

3rd Resistance Point 8.78
2nd Resistance Point 8.57
1st Resistance Point 8.31
Last Price 8.97
1st Support Level 7.84
2nd Support Level 7.63
3rd Support Level 7.37

See More

52-Week High 11.49
Last Price 8.97
Fibonacci 61.8% 7.77
Fibonacci 50% 6.63
Fibonacci 38.2% 5.48
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.